Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6833405 | 1.00 | HTR6 (0.71) | HTR6KDRKAT6A | |
| SCHEMBL3128669 | 0.95 | HTR6 (0.79) | HTR6KDR | |
| Hydrochloric Acid SCHEMBL6833514 | 0.94 | HTR6 (0.78) | HTR6KDR | |
| SCHEMBL6742375 | 0.93 | HTR6 (0.76) | HTR6KDR | |
| Trifluoroacetic Acid SCHEMBL6834351 | 0.92 | HTR6 (0.71) | HTR6KDR | |
| SCHEMBL6747464 | 0.91 | HTR6 (0.79) | HTR6KDR | |
| SCHEMBL6836001 | 0.88 | HTR6 (0.69) | HTR6 | |
| SCHEMBL6747333 | 0.86 | HTR6 (0.71) | HTR6 | |
| SCHEMBL6745380 | 0.86 | HTR6 (0.92) | HTR6KAT6A | |
| SCHEMBL6744764 | 0.85 | HTR6 (0.78) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | PHARMACIA & UPJOHN COMPANY | 2004-02-12 | — | — | US | disclosed |
| WO-2003099797-A1 | SALTS OF BIS-ARYLSULFONES FOR THE TREATMENT OF CNS DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029865-A1 | Sleep disorders; eating disorders; schizophrenia disorders; anxiolytic agents | HCRTR2, HCRTR1, CNR1 | HTR6 76/4885KDR 4880/4885KAT6A 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.